Results 271 to 280 of about 218,137 (296)
Some of the next articles are maybe not open access.
Alcohol, 2020
Engagement of programmed death-1 (PD-1) receptor by its ligands (PD-L1/PD-L2) in activated immune cells is known to be involved in inflammatory neurological disease via a co-inhibitory signal pathway. Interaction of PD-1/PD-L1 is believed to occur only in activated neuroimmune cells because there are undetectable levels of PD-1/PD-L1 in normal ...
Vikas Mishra +4 more
openaire +2 more sources
Engagement of programmed death-1 (PD-1) receptor by its ligands (PD-L1/PD-L2) in activated immune cells is known to be involved in inflammatory neurological disease via a co-inhibitory signal pathway. Interaction of PD-1/PD-L1 is believed to occur only in activated neuroimmune cells because there are undetectable levels of PD-1/PD-L1 in normal ...
Vikas Mishra +4 more
openaire +2 more sources
Journal of Medicinal Chemistry, 2018
The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties ...
Tianyu Wang +6 more
openaire +2 more sources
The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties ...
Tianyu Wang +6 more
openaire +2 more sources
Clinical Cancer Research, 2012
Abstract The aim of T-cell–based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death ...
Daniel S, Chen +2 more
openaire +2 more sources
Abstract The aim of T-cell–based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death ...
Daniel S, Chen +2 more
openaire +2 more sources
European Journal of Cancer, 2013
Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. The most mature results have been obtained in advanced melanoma patients. They indicate important response rates and high quality responses or prolonged duration.
Caroline, Robert +2 more
openaire +2 more sources
Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. The most mature results have been obtained in advanced melanoma patients. They indicate important response rates and high quality responses or prolonged duration.
Caroline, Robert +2 more
openaire +2 more sources
Programmed Death-1/Programmed Death Ligand-1 Inhibitor–Related Pneumonitis and Radiographic Patterns
Journal of Clinical Oncology, 2017Mizuki, Nishino, Hiroto, Hatabu
openaire +2 more sources
European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020
Ümran Kucukgoz Gulec +2 more
exaly
Ümran Kucukgoz Gulec +2 more
exaly